National and Kapodistrian University of Athens
Ο ρόλος της πρωτεΐνης UCH-L1 στη νόσο του Parkinson
Abstract
dc:descriptionParkinson’s disease (PD) is the second most frequent neurodegenerative disorder after Alzheimer’s disease. Its cardinal clinical features include tremor, muscle rigidity, slowness of voluntary movement and postural instability. These symptoms are attributed mainly to a profound reduction of dopamine in the striatum due to a dramatic loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Recent evidence suggests a significant genetic contribution to PD. UCH-L1 gene was genetically linked to PD for the first time when a missense mutation, I93M, was identified in a German family with a PD phenotype. However, this mutation was not found in other families with genetically inherited PD. In addition, many, albeit not all, population studies have shown that a UCH-L1 polymorphism, S18Y, is protective against the development of sporadic PD, and this effect is consistently larger in early onset sporadic cases. Overall, the link of the UCH-L1 gene to PD remains controversial. UCH-L1 is an abundant neuronal protein, member of the Ubiquitin C-terminal Hydrolases (UCHs), involved in ubiquitin proteasome system (UPS)-dependent protein degradation. In vitro data indicate that it indeed acts as a UCH, but whether this occurs in vivo is unclear. Other functions of UCH-L1 within the ubiquitin proteasome system (UPS) have also been proposed, such as an E3 ligase action, or a stabilizer of free ubiquitin. Furthermore, in Aplysia, the UCH-L1 homologue may associate with the proteasome and enhance its activity. Therefore, it is widely postulated that UCH-L1 is functionally linked to PD through the UPS. However, the role of UCH-L1 within the UPS and moreover its relationship to other processes related to PD, such as mitochondrial impairment and oxidative stress, remain unknown. The first aim of this study was to investigate the relationship between changes in UCH-L1 gene and Parkinson’s disease in Greek population. To perform this analysis, we generated a database for PD patients in Greece collecting blood and DNA samples from PD patients and healthy controls from “Attikon” Hospital and the General Hospital of Syros. Overall, 170 PD and 130 control cases were studied using the method of PCR and RFLP (restriction fragment length polymorphism) based on the fact that, in the presence of the S18Y polymorphism, the digestion of the PCR product with a specific enzyme results in the generation of two DNA fragments. The samples from PD patients were compared to control samples, focusing on the S18Y polymorphism, which has been found to be protective against the development of sporadic disease in several population studies, as mentioned earlier, and especially in cases with early age of onset. The analysis of the frequencies of genotypes and alleles that carry the S18Y polymorphism among patients and controls showed that the frequencies were the same between categories. This fact implies that the S18Y carriers in the Greek population don’t have a reduced risk of developing PD compared to carriers of the WT allele. However, the comparative analysis only of sporadic cases with early age of onset showed a trend for S18Y carriers to have a delayed age of onset of the disease compared to homozygotes WT/WT, although this difference did not reach statistical significance. Overall, there does not seem to be a negative genetic association of the S18Y polymorphism with PD, at least in this specific Greek sample. There is however potentially a small protective effect of the S18Y polymorphism on age of onset in sporadic cases that deserves further study. Another goal was to study the role of UCH-L1 within the ubiquitin proteasome system (UPS) and its potential participation in mechanisms related to oxidative stress, given their presumed importance in PD pathogenesis. To examine these issues, we investigated the effects of UCH-L1 overexpression under physiological or oxidative stress conditions by using the mitochondrial toxin MPP+ and hydrogen peroxide (H2O2). We discovered that S18Y, but not wild type (WT), UCH-L1 expression in human neuroblastoma cells SH-SY5Y and primary cortical neurons leads to a specific (not observed against other insults, such as proteasomal inhibition or DNA damage) protection from MPP+- and H2O2-induced Reactive Oxygen Species generation and death, linking for the first time this genetic variant with protection from oxidative stress. MPP+ is the active metabolite of MPTP which is a mitochondrial neurotoxin capable of causing Parkinsonism in humans and in animal models. By generating hybrid mutants of S18Y, we showed that this anti-oxidant effect is independent of its known ubiquitin-binding competency or catalytic activity. Importantly, the anti-oxidant effect of S18Y UCH-L1 is potentially quite relevant as a therapeutic target, as it occurs early, at a still unknown point upstream of ROS generation, perhaps linked to the lysosomes, where UCH-L1 has been postulated to act. Moreover, we were able to observe such effects when the levels of the overexpressed protein were similar to the endogenous, despite high transfection efficiency, indicating that these effects occur at physiological levels of expression of this variant in human cells. Regarding the link of UCH-L1 to UPS, we have shown that neither WT nor S18Y UCH-L1 appear to directly impact the proteasome, although they both lead to stabilization of free ubiquitin, as previous studies have reported. In addition, the absence of WT mouse UCH-L1 in neurons derived from gad mice (UCH-L1 KO mice), led to a decrease of free ubiquitin, but no overall decrease in UPS function or enhanced sensitivity to oxidative stress, indicating again that endogenous WT UCH-L1 does not exert an antioxidant function, further reinforcing the unique property of the S18Y variant. Importantly, overexpression of S18Y, but not WT, UCH-L1 in primary cortical neurons by adenoviral infection confirmed the general protective effect of S18Y against MPP+-induced death, previously observed at a single cell level, and showed a clear tendency to preserve axonal morphology. Moreover, WT or S18Y overexpression in differentiated SH-SY5Y cells inducibly expressing α-synuclein (AS) did not affect AS-induced toxicity despite the presumed interaction between UCH-L1 and AS. These results indicate that the protective function of S18Y is selective for oxidative insults. Based on our results achieved in cell culture, we extended this study to the adult nigral dopaminergic system of mice in order to further investigate the physiological function of WT UCH-L1 under oxidative stress conditions in vivo. To study the effect of UCH-L1 gene to neurodegeneration caused by MPTP toxin in vivo, we exposed both gad mice and their corresponding WT littermates to MPTP and assessed the potential differential effects on striatal dopamine and TH content and substantia nigra neuron number. Gad mice did not show dysfunction of the dopaminergic system and moreover were not more vulnerable regarding their response to MPTP. These results confirmed the first indications from the in vitro experiments that the WT UCH-L1 protein does not possess, even to a lesser extent, an anti-oxidant capacity similar to S18Y UCH-L1 in vivo. The data from this study suggest that the S18Y UCH-L1 variant confers a novel anti-oxidant function not present in the WT form, which may underlie the protective effects of this variant in certain PD populations. Our results provide also indirect evidence for the importance of oxidative stress as a pathogenetic factor in sporadic PD and may reveal new mechanisms through which UCH-L1 might be linked to PD pathogenesis. Such results may open the avenue for the discovery of potential novel therapeutic responses in PD that are based on innate mechanisms of defense against neurotoxicity related to oxidative stress.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Κυρατζή, Έλλη
- Kyratzi, Elli
Subjects
dc:subject × 16- Νόσος Parkinson
- Οξειδωτικό στρες
- Σύστημα ουμπικουιτίνης-πρωτεασώματος
- Πολυμορφισμοί
- Αντιδραστικές ενώσεις οξυγόνου
- Μιτοχονδριακή τοξίνη MPTP
- Parkinson's disease
- Oxidative stress
- Ubiquitin-proteasome system
- Polymorphisms
- Reactive oxygen species (ROS)
- Mitochondrial toxin MPTP
- Ιατρική και Επιστήμες Υγείας
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/31575